跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分66

个体化卵巢癌新抗原疫苗 I 期试验:10 例接种者中 8 例出现靶向免疫应答

Personalized ovarian cancer vaccines spark immunity in phase 1 trial

AI 导读

一项 I 期试验中,个体化新抗原疫苗 NeoVax 联合标准化疗和 nivolumab 用于高级别上皮性卵巢癌,10 例接种者中 8 例出现针对肿瘤突变的靶向免疫应答。全部 10 例均完成治疗,未因毒性反应停药,血液中可检出识别肿瘤突变的持久 T 细胞。研究共入组 22 例,仅 10 例进入接种阶段,结果发表于 Nature Medicine。

推荐理由

I 期试验报告个体化新抗原疫苗在高级别卵巢癌的免疫应答与安全性,10 例中 8 例出现靶向反应。

正文 · 原文
Personalized ovarian cancer vaccines spark immunity in phase 1 trial
Evaluation of tumor microenvironment and TIL specificities from tumor biopsies. Credit: Nature Medicine (2026). DOI: 10.1038/s41591-026-04717-8

Rapidly dividing cancer cells can develop DNA mutations that produce abnormal proteins called antigens, which are unique to each patient's cancer. Scientists are now testing personalized cancer vaccines that target these neoantigens and prevent cancer from returning after treatment.

A recent phase 1 clinical trial tested whether a personalized cancer vaccine called NeoVax could be safely manufactured and administered alongside standard treatment for patients with high-grade epithelial ovarian cancer.

Researchers sequenced the DNA and RNA of both cancer and healthy cells from newly diagnosed patients and those with recurring cancer to identify their neoantigens. Based on these unique targets, they custom-built the NeoVax, which contained a neoantigen-targeting personalized pool of peptides for each individual.

The researchers successfully manufactured personalized vaccines and administered them alongside standard chemotherapy and immunotherapy.

The vaccine was designed to train the immune system, particularly T cells, to recognize and destroy cancer cells carrying specific mutations. They saw that NeoVax triggered a targeted immune response in eight of the 10 vaccinated patients. The vaccine also generated long-lasting T cells in the blood that could recognize these specific tumor mutations.

The findings are published in Nature Medicine.

Personalized ovarian cancer vaccines spark immunity in phase 1 trial
cfDNA VAF for vaccine target and non-target missense SNVs. Credit: Nature Medicine (2026). DOI: 10.1038/s41591-026-04717-8

Tailored cancer cell attackers

About 80% of epithelial ovarian cancers are the high-grade serous type, which carries mutations in a gene called TP53. These cancers are particularly difficult to treat with immunotherapy because they often suppress immune attacks and have relatively few mutations for the immune system to recognize; as a result, standard immunotherapy drugs that worked well against some cancers have response rates below 10%. The cancer also frequently returns after initial treatment.

Researchers wanted to test whether personalized vaccines could help prevent this recurrence. They planned to give the vaccines immediately after standard chemotherapy, when the amount of tumor remaining is at its lowest.

The team initially enrolled 22 patients—9 newly diagnosed patients in cohort A and 13 patients with recurrent cancer in cohort B—but only 10 could proceed to the vaccination stage. Researchers collected pretreatment tumor tissue biopsies and healthy blood samples from each patient and ran whole-exome sequencing (WES) to identify DNA mutations unique to each tumor.

With these mutations identified, the team created synthetic peptide chains, each 15–33 amino acids long, carrying the selected mutation targets. They divided the custom peptides into four personalized injection pools (A–D) and mixed them with poly-ICLC, an immune stimulant that alerts immune cells at the injection site. Patients also later received an anti-PD-1 antibody, which helps immune cells attack cancer.

Before vaccination began, all patients completed standard platinum-based doublet chemotherapy. After treatment, the researchers tracked tumor growth and collected blood samples at regular intervals to see whether the vaccine had activated T cells against the targeted peptides. For patients with available postvaccination tumor biopsies, the team tested whether vaccine-trained T cells directly recognized and attacked the patient's actual tumor cells.

Immunity in action

The personalized NeoVax vaccine, given alongside the immunotherapy drug nivolumab, showed a manageable safety profile. All 10 vaccinated participants completed treatment without having to stop because of toxic side effects.

Despite a median gap of 6.5 months between initial tumor biopsy and vaccination, more than 70% of the targeted mutations were still detectable in the blood. They found that patients whose cancer stayed under control developed immune responses against a wider range of targeted mutations than those whose cancer continued to progress.

Blood-marker analyses suggested that the treatment may have been biologically active in six patients. Three experienced temporary disease control, while the other three had more sustained control, and four patients experienced continuous, unabated tumor growth.

The researchers suggest that personalized cancer vaccines may have the greatest impact when given alongside first-line treatment, while the amount of cancer remaining in the body is at its lowest. Future trials will need to investigate how tumors develop resistance to treatment to better establish how vaccine effectiveness can be demonstrated in hard-to-treat cancers such as high-grade ovarian cancer.

Written for you by our author Sanjukta Mondal, edited by Gaby Clark, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

MacLean C. Sellars et al., Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial, Nature Medicine (2026). DOI: 10.1038/s41591-026-04717-8

Journal information: Nature Medicine

Key medical concepts

NeoantigensNivolumab

Who's behind this story?

Sanjukta Mondal

Sanjukta Mondal

Master's in Chemistry. Freelance science journalist and communicator. Published in Chemistry World, BioSpace, and The Hindu. Full profile →

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Personalized ovarian cancer vaccines spark immunity in phase 1 trial (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-personalized-ovarian-cancer-vaccines-immunity.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com